Cancer Center Support Grant

项目概要 自 2012 年对该癌症中心支持补助金 (CCSG) 进行最后一次竞争性审查以来，NCI 指定的 珀尔马特癌症中心 (PCC)，前身为纽约大学癌症研究所，经受住了 超级风暴桑迪进入了一个深刻变革和扩张的时期。由一个推动 Laurie 和 Isaac Perlmutter 的变革性礼物，纽约大学更新和加强的机构支持 Langone Health 系统 (NYULH) 和一位新主任，我们彻底改革了我们的领导团队，扩大了我们的 临床和研究设施，并制定了新的战略愿景并开始实施新的战略 计划。在该计划的指导下，我们的科学计划和共享资源进行了重组，我们 开展了一项重大招聘活动，新增了 12 名新领导层和/或高级教员 招募了 15 名新癌症中心教员，总共 68 名新成员。正在修订中，更多 根据严格的标准，会员人数已精简为 180 名正式会员和 56 名准会员。会员 开展研究作为 5 个科学计划的一部分：癌症基因组动力学、癌细胞生物学、肿瘤 免疫学、黑色素瘤或流行病学和癌症控制，由 10 个共享资源和 2 个资源协助 开发共享资源。我们的临床试验办公室已经重组并大幅扩大 在新的领导下，新的一期单位已经开业。随后，试验的可用性、质量和应计费用 增加了，而试营业的时间却明显缩短了。与我们增加的 地理范围和患者群体，我们重新定义并扩大了我们的服务区域。协助下 在纽约大学朗格尼医学院和纽约大学医学院设立新的人口健康系 纽约大学主校区的全球公共卫生，我们的人口科学研究广度有所增加 和质量。最重要的是，我们的实验室科学家取得了范式转变的发现，我们的临床医生 领导了多项改变实践的试验，我们的人口科学家对这一问题产生了新的见解 癌症的成因以及如何控制该疾病，促成了重大公共卫生政策的变化， 倡议，并建立了新的社区外展计划，以解决特定的癌症负担和 我们学区的健康差距。尽管 PCC 位于一个拥有其他四个 NCI 指定城市的城市 癌症中心，我们的服务区域与其他区域有很大不同：我们是降低癌症中心的主要提供者 曼哈顿，并扩展到布鲁克林，纽约市最大且发展最快的行政区 以及皇后区和长岛。

Project Summary Since the last competitive review of this Cancer Center Support Grant (CCSG) in 2012, the NCI-designated Perlmutter Cancer Center (PCC), previously NYU Cancer Institute, has weathered the devastation of Superstorm Sandy and emerged into a period of profound transformation and expansion. Propelled by a transformative gift from Laurie and Isaac Perlmutter, renewed and enhanced institutional support from the NYU Langone Health system (NYULH) and a new Director, we have overhauled our leadership team, expanded our clinical and research facilities, and developed a new strategic vision and began implementing a new Strategic Plan. Guided by this plan, our Scientific Programs and Shared Resources have been restructured, and we embarked on a major recruitment campaign that has yielded 12 additional new leadership and/or senior faculty recruits, 15 other new cancer center faculty recruits, and 68 new members overall. Under revised, more stringent criteria, membership has been streamlined to 180 full members and 56 associate members. Members carry out research as part of 5 Scientific Programs, Cancer Genome Dynamics, Cancer Cell Biology, Tumor Immunology, Melanoma, or Epidemiology and Cancer Control, assisted by 10 Shared Resources and 2 Developing Shared Resources. Our clinical trials office has been reorganized and substantially expanded under new leadership and a new Phase I unit has opened. Subsequently, trial availability, quality, and accrual have increased, while the time to trial opening has been markedly reduced. In line with our increased geographic scope and patient population, we have redefined and enlarged our catchment area. Aided by the creation of a new Department of Population Health at NYU Langone School of Medicine and the College of Global Public Health at the NYU main campus, our Population Sciences research has increased in breadth and quality. Most importantly, our laboratory scientists have made paradigm-shifting discoveries, our clinicians have led multiple practice-changing trials, and our population scientists have yielded new insights into the causes of cancer and how to control the disease, contributed to major public health policy changes and initiatives, and established new community outreach programs that address the specific cancer burdens and health disparities in our catchment area. Although PCC is located in a city with four other NCI-designated cancer centers, our catchment area differs substantially from the others: we are the major provider to lower Manhattan, and have expanded into Brooklyn, the largest and fastest growing borough in New York City, as well as to Queens and Long Island.